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Inhibition of Mast Cell Degranulation by a Chimeric Toxin Containing a Novel
Phosphatidylinositol-3,4,5-Triphosphate Phosphatase
Abstract
It is well established that many cell functions are controlled by the PI-3K signaling pathway and the
signaling lipid, phosphatidylinositol-3,4,5-triphosphate (PIP3). This is particularly true for mast cells which
play a key regulatory role in allergy and inflammation through activation via high-affinity IgE receptors
(Fce{open}RI) leading to activation of signaling cascades and subsequent release of histamine and other
pro-inflammatory mediators. A pivotal component of this cascade is the activation of PI-3K and a rise in
intracellular levels of PIP3. In this study, we developed a novel chimeric toxin that selectively binds to
mast cells and which functions as a PIP3 phosphatase. Specifically, the chimeric toxin was composed of
the Fce{open}RI binding region of IgE and the active subunit of the cytolethal distending toxin, CdtB, which
we have recently demonstrated to function as a PIP3 phosphatase. We demonstrate that the chimeric
toxin retains PIP3 phosphatase activity and selectively binds to mast cells. Moreover, the toxin is capable
of altering intracellular levels of PIP3, block antigen-induced Akt phosphorylation and degranulation.
These studies provide further evidence for the pivotal role of PIP3 in regulating mast cell activation and
for this signaling lipid serving as a novel target for therapeutic intervention of mast cell-mediated disease.
Moreover, these studies provide evidence for the utilization of CdtB as a novel therapeutic agent for
targeting the PI-3K signaling pathway. © 2010 Elsevier Ltd.
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a b s t r a c t
It is well established that many cell functions are controlled by the PI-3K signaling pathway and the
signaling lipid, phosphatidylinositol-3,4,5-triphosphate (PIP3). This is particularly true for mast cells
which play a key regulatory role in allergy and inﬂammation through activation via high-afﬁnity IgE
receptors (FcRI) leading to activation of signaling cascades and subsequent release of histamine and
other pro-inﬂammatory mediators. A pivotal component of this cascade is the activation of PI-3K and a
rise in intracellular levels of PIP3. In this study, we developed a novel chimeric toxin that selectively binds
to mast cells and which functions as a PIP3 phosphatase. Speciﬁcally, the chimeric toxin was composed
of the FcRI binding region of IgE and the active subunit of the cytolethal distending toxin, CdtB, which
we have recently demonstrated to function as a PIP3 phosphatase. We demonstrate that the chimeric
toxin retains PIP3 phosphatase activity and selectively binds to mast cells. Moreover, the toxin is capable
of altering intracellular levels of PIP3, block antigen-induced Akt phosphorylation and degranulation.
These studies provide further evidence for the pivotal role of PIP3 in regulating mast cell activation
and for this signaling lipid serving as a novel target for therapeutic intervention of mast cell-mediated
disease. Moreover, these studies provide evidence for the utilization of CdtB as a novel therapeutic agent
for targeting the PI-3K signaling pathway.
© 2010 Elsevier Ltd. All rights reserved.

1. Introduction
Mast cells play a key regulatory role in allergy and inﬂammation through the activation of high-afﬁnity IgE receptors (FcRI)
and subsequent release of histamine and other pro-inﬂammatory
mediators (Kinet, 2007; Rivera and Olivera, 2008). Mast cell activation is dependent upon the binding of multivalent antigen to
prebound IgE molecules leading to cross-linking of FcRI. As a
consequence of these events, a complex signaling cascade is activated leading to degranulation, synthesis of pro-inﬂammatory lipid
mediators and cytokines. The high-afﬁnity FcRI is composed of an
␣-chain which is responsible for binding the Fc portion of IgE, a
␤-chain and two ␥-chains. Upon antigen binding and FcRI crosslinking, immunoreceptor tyrosine-based activation motifs (ITAMS)
on the ␤- and ␥-subunits become phosphorylated and then serve

Abbreviations: PIP3, phosphatidylinositol-3,4,5-triphosphate; FcRI, highafﬁnity IgE receptors; Cdt, cytolethal distending toxin; BMMC, bone marrow derived
murine mast cells; MCF, mean channel ﬂuorescence.
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School of Dental Medicine, 240 South 40th Street, Philadelphia, PA 19104-6030,
United States. Tel.: +1 215 898 5959; fax: +1 215 573 2050.
E-mail address: shenker@pobox.upenn.edu (B.J. Shenker).
0161-5890/$ – see front matter © 2010 Elsevier Ltd. All rights reserved.
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as docking sites for secondary signaling proteins such as the tyrosine kinases Lyn and Syk. These molecular interactions increase
tyrosine phosphorylation events and increase enzymatic activity
of signaling proteins at or near the receptor complex. Additionally,
signaling pathways leading to mast cell activation are dependent
upon protein-lipid interactions. In particular, the generation of
the signaling lipid, phosphatidylinositol-3,4,5-triphosphate (PIP3),
has been shown to be critical for mediating mast cell activation
(reviewed by Nadler et al., 2001).
Phosphoinositides (PIs) are derivatives of phosphatidylinositol
and while they represent minor components of membrane lipids,
PIs regulate a wide range of biological processes including: cell
proliferation, cell survival, differentiation, cytoskeleton organization and membrane trafﬁcking (reviewed in Kraub and Haucke,
2007; Sasaki et al., 2007). PIs regulate these cellular processes by
serving as site-speciﬁc membrane signals that mediate membrane
recruitment and regulation of effector/signaling proteins (Lemmon,
2008). PIP3 is synthesized from PI(4,5)P2 following the activation
of PI-3K and has received much attention for its critical role as a second messenger. In particular, FcRI-mediated mast cell activation
requires the recruitment and activation of PI-3K and concomitant
synthesis of PIP3 (Rivera and Olivera, 2008; Abramson and Pecht,
2007; Nadler et al., 2001; Tkacyzk and Gilﬁllan, 2001). The generation of PIP3 is critical to recruiting pleckstrin homology domain

204

B.J. Shenker et al. / Molecular Immunology 48 (2010) 203–210

containing proteins such as BTK, Akt and PDK1 to the plasma
membrane where they become activated and coupled to upstream
signals and, in turn, transduce those signals to downstream events
ultimately leading to activation of the secretory and synthetic
response. Thus, FcRI-mediated mast cell degranulation, synthesis
of lipid derived pro-inﬂammatory mediators and cytokine production is ultimately controlled by PIP3 thereby making this lipid
messenger a potent target for pharmacologic intervention in treating mast cell-mediated allergic disorders.
Several investigators have demonstrated that a reduction in
PI-3K activity resulting from mutations or the introduction of
inhibitors results in decreased PIP3 synthesis with a concomitant
inhibition of cell function (reviewed in Kim et al., 2008). Of particular relevance, we have recently demonstrated that the active
subunit of the cytolethal distending toxin (Cdt), CdtB, exhibits
potent PIP3 phosphatase activity making it a useful agent to modulate PIP3 signaling pathways and to advance our understanding
of the role of PIP3 in regulating mast cell activation (Shenker et
al., 2007). We now report on the effect of a novel chimeric toxin
composed of CdtB to speciﬁcally deplete cells of PIP3 and the FcRI
binding region of IgE to confer mast cell speciﬁcity in order to inhibit
the FcRI/PI-3K/PIP3 signaling pathway. Our results clearly indicate that the chimeric toxin not only speciﬁcally binds to mast
cells, but is capable of inhibiting antigen-IgE-mediated mast cell
degranulation.
2. Materials and methods
2.1. Cell culture
RBL-2H3 cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum,
glutamine (2 mM), penicillin (100 units/ml) and streptomycin
(100 g/ml) (Venkatesha et al., 2004). Murine bone marrow derived
mast cells were (BMMC) derived from bone marrow cells obtained
from the femurs of C57/BL6mice (Zaidi et al., 2006). Cells were
cultured for 4–6 weeks in Iscove’s medium supplemented with
10% fetal bovine serum, glutamine (2 mM) penicillin (100 units/ml),
streptomycin (100 g/ml), and rmIL-3 (10 ng/ml). The homogeneity of the mast cells was conﬁrmed by acid toluidine blue
staining; the cell population used for these studies was >95%
BMMC.
2.2. Assay of degranulation
RBL-2H3 and BMMC were incubated overnight in the presence
of 1 g/ml anti-dinitrophenyl (DNP) mouse IgE (Sigma Chemical,
St. Louis, MO). Cells (5 × 104 ) were seeded into 96-well plates in a
total volume of 50 l of HEPES-buffered saline containing 0.1% BSA
and exposed to DNP-BSA (Bioresearch Technologies; Novato, CA)
for 30 min. For total ␤-hexosaminidase release, control cells were
lysed in 50 l of 0.1% Triton X-100. Aliquots of supernatants or cell
lysates were incubated with 1 mM p-nitrophenyl-N-acetyl-␤-Dglucosamine for 1.5 h at 37 ◦ C. The reaction was stopped by adding
250 l of a 0.1 M Na2 CO3 /0.1 M NaHCO3 buffer and absorbance was
measured at 405 nm (Ali et al., 1993).
2.3. Construction and expression of chimeric toxin
Construction of the plasmid containing wildtype cdtB gene
(pGEMCdtB) was previously described (Shenker et al., 2005). In
order to construct the plasmid containing the cdtB gene fused to
the coding sequence for the Fc binding region of IgE, designated
pIVEXCdtBFc, we inserted NcoI and NotI restriction sites by PCR
using pGEMCdtB as a template with the following primers:

CAT GCC ATG GCA AAC TTG AGT GAT TTC AAA GTA GCA
ATA GTT TAG CGG CCG CGA TCA CGA ACA AAA CTA ACA GGA
A new plasmid (pIVEXCdtB) containing cdtB was generated from
the PCR product which was ligated into pIVEX2.3d (Roche Applied
Science; Indianapolis, IN). The Fc fragment was generated by
PCR using cDNA obtained from LPS activated murine B-cells as
described (Belostotsky and Lorberboum-Galski, 2003); the following primers were used to incorporate NotI and XmaI restriction sites
into the PCR product:
ATA AGA ATG CGG CCG CCA GCA ATG GAT GTC TGA AAG CA
CCC CCC GGG TGG GGT CTT GGT GAT GGA ACG CA
The PCR product contains 411 residues encoding 135 amino
acids corresponding to residues 137–271 of the mouse IgE heavy
chain (Genbank accession J00476); this sequence corresponds to
the C terminus of domain 2 and domain 3. The PCR product
was ligated into pIVEXCdtB to yield a new plasmid designated,
pIVEXCdtBFc. The chimeric protein was expressed using an in vitro
coupled translation/transcription system (RTS 500 ProteoMaster;
Roche Applied Science) that we routinely employ and the protein
puriﬁed by nickel afﬁnity chromatography as we incorporate a His
tag into the construct (Shenker et al., 2004, 2005).
2.4. Phosphatase assay
Phosphatase activity was assessed by monitoring the dephosphorylation of PIP3 as described by Maehama et al. (2000) and
Shenker et al. (2007). Brieﬂy, the reaction mixture (20 l) consisted
of 100 mM Tris–HCl (pH 8.0), 10 mM dithiothreitol, 0.5 mM diC16phosphatidylserine (Avanti Polar Lipids, Alabaster, AL), 25 M PIP3
(diC16, Echelon Biosciences, Salt Lake City, UT) and the indicated
amount of toxin. Lipid solutions were deposited in 1.5 ml tubes,
organic solvent removed, the buffer added and a lipid suspension
formed by sonication. Phosphatase assays were carried out at 37 ◦ C
for 30 min; the reactions were terminated by the addition of 15 l of
100 mM N-ethylmaleimide. Inorganic phosphate levels were then
measured using a malachite green assay. Malachite green solution [Biomol Green (Biomol, Plymouth Meeting, PA)] was added
to 100 l of the enzyme reaction mixture and color was developed
for 20 min at RT. Absorbance at 650 nm was measured and phosphate release quantiﬁed by comparison to inorganic phosphate
standards.
2.5. Measurement of cellular PIP3 content
BMMC (5 × 105 ml−1 ) were incubated in the presence of
medium or toxin for the time indicated. Replicate cultures
(1 × 107 cells) were pooled and harvested. The cell pellet was
treated with cold 0.5 M TCA for 5 min, centrifuged and the pellet
washed twice with 5% TCA containing 1 mM EDTA. Neutral lipids
were extracted twice with methanol:chloroform (2:1) at RT. Acidic
lipids were extracted with 2.25 ml methanol:chloroform:12 M HCl
(80:40:1) for 15 min at RT; the samples were centrifuged for
5 min and the supernatant recovered. The supernatant was then
treated with 0.75 ml chloroform and 1.35 ml 0.1 M HCl and centrifuged to separate organic and aqueous phases; the organic
phase was collected and dried. The dried lipids were resuspended in 50 mM Hepes buffer (pH 7.4) containing 150 mM
NaCl and 1.5% sodium cholate, and left overnight at 4 ◦ C. PIP3
levels were then determined using a commercially available competitive ELISA according to the manufacturers directions (PIP3
Mass ELISA Kit and PIP2 Mass ELISA Kit; Echelon Biochemicals).
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2.6. Immunoassays
Samples were separated on 12% SDS-PAGE gels and then transferred to nitrocellulose. The membrane was blocked with BLOTTO
and then incubated with anti-CdtB mAb (CdtB194), anti-Akt (Cell
Signaling Technology, Danvers, MA) or anti-pAkt antibody (pAkt
473; Cell Signaling Technology) for 18 h at 4 ◦ C (Shenker et al.,
1999). Membranes were washed, incubated with goat anti-mouse
immunoglobulin (Southern Biotech, Birmingham, AL) conjugated
to horseradish peroxidase. The Western blots were developed
using chemiluminescence [SuperSignal West Pico (Thermo Scientiﬁc, Rockford, IL)] and analyzed by digital densitometry (Kodak
Scientiﬁc Imaging Systems, Rochester, NY).
In order to determine if CdtBFc inﬂuenced mast cell sensitization with IgE, BMMC were incubated with IgE as described above.
Cells were then treated with CdtBFc (20 g/ml) for 2 h min. The
cells were then stained with anti-IgE conjugated to FITC (Southern
Biotech) and analyzed by ﬂow cytometry.
3. Results
The plasmid expressing the CdtB-IgE Fc chimeric protein
(pIVEXCdtBFc) was constructed in pIVEX (Roche) as described
in Materials and Methods section; the insert contains 1207 bp
that encodes a fusion toxin protein consisting of 135 aa encoding the FcRI binding region from the CH2/CH3 region of IgE and
the entire sequence for CdtB (32 kDa; Fig. 1A). Expression of the
chimeric protein was achieved using an in vitro coupled translation/transcription system and the protein puriﬁed by nickel afﬁnity
chromatography as we incorporated a His tag into the construct
(Shenker et al., 2004, 2005). Fig. 1B and C shows SDS-PAGE and
Western blot analysis of samples containing both crude and puriﬁed CdtBFc that was expressed from pIVEXCdtBFc using the in
vitro coupled translation/transcription system. The chimeric toxin
(CdtBFc ) exhibits a mw of approximately 49 kDa compared to
32 kDa for CdtBWT .
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CdtBFc was assessed for its ability to dephosphorylate PIP3
using malachite green to measure inorganic phosphate release.
As shown in Fig. 2A, CdtBFc exhibits dose-dependent phosphate
release which ranged from 0.5 ± 0.03 to 1.5 ± 0.17 nmol/30 min
in the presence of 0.125 and 1.0 M CdtBFc , respectively. For
comparative purposes, CdtBWT was also assessed. CdtBWT also
exhibits dose-dependent phosphate release which was lower than
the chimeric toxin; phosphate release ranged from 0.1 ± 0.02
to 0.96 ± 0.07 nmol/30 min in the presence of 0.125 and 1.0 M
CdtBFc . We have previously demonstrated that CdtBWT exhibits
Michaelis–Menten kinetics (Shenker et al., 2007). Therefore, to further assess the phosphatidylinositol phosphatase activity of CdtBFc
we compared the Michaelis–Menten kinetics to that of CdtBWT
and determined Km and Vmax values with respect to cleavage of
PIP3 (Fig. 2B and C). By this analysis, both CdtBFc and CdtBWT
demonstrated Km values of 593.7 and 124.3 M, respectively.
Vmax values were 0.117 nmol/min (CdtBFc ) and 0.055 nmol/min
(CdtBWT ) for 0.5 M toxin. Thus, the chimeric toxin exhibits
approximately twice the PIP3 phosphatase activity along with
reduced substrate afﬁnity compared to that observed with wildtype
CdtB.
We next determined whether CdtBFc was capable of selectively
interacting with mast cells by binding to FcRI. BMMC and Jurkat
cells were exposed to varying amounts (0–10 g/ml) of CdtBFc for
60 min. The cells were then extensively washed, solubilized and
analyzed by Western blot with anti-CdtB mAb (Fig. 3A). CdtBFc
was detected in extracts prepared from both BMMC and RBL cells
(data not shown). The speciﬁcity of this interaction is demonstrated
by the fact that Jurkat cells, which do not contain FcRI, failed to
bind the chimeric toxin. CdtBWT failed to associate with cells (data
not shown); this observation is consistent with our earlier studies
indicating that CdtB requires the binding units, CdtA and CdtC, in
order for it to bind to lymphocytes (Shenker et al., 2005). These
studies were extended to demonstrate speciﬁcity of CdtBFc binding to the FcRI. As shown in Fig. 3B, pre-exposure of BMMC to
varying amounts of IgE (1–10 g/ml) blocked CdtBFc binding.

Fig. 1. Expression of CdtBFcε chimeric toxin. Panel A is a schematic representation of the protein encoded by pIVEXCdtBFc showing the CdtB subunit on the N-terminus of
the chimera (blue), the Fc binding region downstream (red) and the histidine tag (green) on the C terminus. CdtBFcε was expressed from pIVEXCdtBFc using in vitro coupled
translation/transcription system and puriﬁed as described in Section 2; panel B shows a Coomassie stained SDS-PAGE gel of the unpuriﬁed expressed protein (lane 1) and
the puriﬁed chimeric toxin (lane 2). Panel C shows a Western blot analysis of the expressed chimeric toxin which exhibits a mw of approximately 47 kDa; this compares to
32 kDa for CdtBwt . (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of the article.)
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Fig. 2. Analysis of CdtBFcε for PIP3 phosphatase activity. Varying amounts of CdtBWT (squares) and CdtBFcε (circles) were assessed for their ability to hydrolyze PIP3 in vitro as
described in Section 2 (panel A). The amount of phosphate release was measured using a malachite green binding assay. Data are plotted as phosphate release (nmol/30 min;
mean ± S.D.) versus protein concentration. CdtBFc exhibited dose-dependent phosphatase activity; results are the mean ± S.D. of three experiments. The rate of CdtBFc
(0.5 M; panel B) and CdtBWT (0.5 M; panel C) mediated phosphate release in the presence of varying concentrations of PIP3 was assessed. Data were analyzed using
Michaelis–Menten kinetics; Km values for CdtBwt and CdtBFc were 124.3 and 593.7 M, respectively and Vmax were 0.055 nmol/min (CdtBwt ) and 0.117 nmol/min (CdtBFc ).

We next assessed whether the chimeric toxin was also capable
of entering cells and exhibit PIP3 phosphatase activity by assessing
the intracellular levels of both PIP3 and the degradative product,
PI-3,4-P2. RBL cells were treated with CdtBFc (10 g/ml) for varying periods of time and the levels of PIP3 determined (Fig. 4A).
Toxin-treated cells exhibited a time-dependent reduction in PIP3;
baseline levels were reduced from 10.9 ± 0.14 pmol/107 cells to
9.6 ± 0.88 and 7.0 ± 0.47 pmol/107 cells at 30 and 60 min, respectively. Reductions in PIP3 levels were also dependent upon the
dose of chimeric toxin employed (data not shown). A concomitant

increase in the levels of PI-3,4-P2 (Fig. 4B) was observed from a
baseline of 0.33 ± 0.03 pmol/107 cells to 0.67 ± 0.13 and 1.3 ± 0.03
at 30 and 60 min, respectively. Similar results were observed with
BMMC (data not shown). It should be noted that in the absence of
CdtA and CdtC, CdtBwt was not able to alter phosphatidylinositol
levels.
The next series of experiments focused on whether CdtBFc
was capable of inhibiting antigen-IgE-FcRI mediated activation
of mast cells. For these studies we employed both RBL cells and
murine BMMC and assessed the ability of the toxin to inhibit

Fig. 3. Selective binding of CdtBFc to mast cells. BMMC and Jurkat cells were exposed to varying amounts of CdtBFc for 60 min at 4 ◦ C (panel A). The cells were washed,
solubilized and analyzed by SDS-PAGE and Western Blot using anti-CdtB mAb. CdtBFc was observed in BMMC samples, but not with Jurkat cells. Similar results were observed
with RBL cells (data not shown). It should be noted that CdtBwt does not bind to either Jurkat cells or BMMC (data not shown). Panel B is a Western blot demonstrating that
the binding of CdtBFc to BMMC can be blocked by pre-exposing cells (30 min) to varying amounts of IgE prior to the addition of chimeric toxin.
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Fig. 4. Analysis of CdtBFc -induced changes in PIP3 and PI-3,4-P2 levels in RBL cells. RBL cells were incubated with CdtBFc (10 g/ml) for 15–60 min. Lipids were then
extracted; PIP3 (panel A) and PI-3,4-P2 (panel B) levels were determined by ELISA. Results are the mean ± S.D. of three experiments. The chimeric toxin induced a time
dependent reduction in PIP3 and increase in PI-3,4-P2.

Fig. 5. Effect of CdtBFc on mast cell degranulation. RBL cells (left panel) and BMMC (right panel) were sensitized to anti-DNP IgE. Varying concentrations of CdtBFc (circles)
or CdtBwt (triangles) were added to cells 60 min prior to exposure to antigen (DNP-BSA). Degranulation was measured 30 min after the addition of antigen as a function
of the release of ␤-hexosaminidase. Data are expressed as percent control (sensitized cells treated with antigen in the absence of toxin) and are the mean ± S.D. of three
experiments. CdtBFc inhibited degranulation in both RBL and BMMC. All data points are statistically signiﬁcant differences (p < 0.05) between CdtBFc and CdtBwt except for
the 10 g/ml values for BMMC (p = 0.138).

antigen (DNP)-induced degranulation in anti-DNP IgE sensitized
cells. As shown in Fig. 5, CdtBFc -treated RBL cells exhibit a dosedependent inhibition of DNP-induced degranulation measured as a
function of ␤-hexosaminidase release. Degranulation was reduced
from 100% in control cells (exposed to antigen in the absence
of of toxin) to 76.5%, 67% and 43% in the presence of 1.25, 5.0
and 20.0 g/ml CdtBFc , respectively. In contrast, degranulation
was minimally impaired in cells similarly treated with CdtBWT ;
␤-hexosaminidase release was 81.8% ± 2.7 in cells treated with
20 g/ml CdtBWt . In a parallel series of experiments, the chimeric
toxin was also assessed for its ability to inhibit BMMC degranulation. CdtBFc reduced ␤-hexosaminidase release to 47.7% ± 10.9
in the presence of 1.25 g/ml CdtBFc and to 38.7% ± 11.4 in
the presence of 20 g/ml chimeric toxin. CdtBWT had a minimal
effect on degranulation as exposure to 20 g/ml only reduced
␤-hexosaminidase release to 79%. In addition to degranulation,
targets downstream of PIP3 were also assessed. Fig. 6 demonstrates the effect of CdtBFc on IgE-FcRI-mediated activation of
mast cells as a function of phosphorylation of Akt (pAkt), a PIP3 dependent event. Antigen activation of mast cells resulted in
increased pAkt within 2 and 5 min in sensitized BMMC. By contrast, BMMC treated with CdtBFc exhibited reduced pAkt at both 2
and 5 min.
Finally, we wanted to eliminate the possibility that CdtBFc
impairment of mast cell function was the result of reduced IgE binding to BMMC as opposed to direct effects of reduced PIP3 levels.
The chimeric toxin was assessed for its ability to reduce IgE sensitization of BMMC. As shown in Fig. 7, BMMC were incubated in
medium alone or containing CdtBFc (controls); additionally, cells
were sensitized to IgE (panels C and D) as described in Section 2

and then incubated in medium (panel C) or with CdtBFc (panel D)
for 2 h. Surface IgE binding was assessed by immunoﬂuorescence
following staining of cells with anti-IgE conjugated to FITC and ﬂuorescence measured by ﬂow cytometry. CdtBFc did not reduce IgE
binding to mast cells as evident by the level of immunoﬂuorescence; mean channel ﬂuorescence (MCF) was 12.7 in control cells
sensitized with IgE and 13.4 in cells pre-exposed to CdtBFc . Background MCF for control cells that were not treated with chimeric
toxin or IgE was5.6. It should be noted that the immunoﬂuores-

Fig. 6. Western blot analysis of pAkt during BMMC activation. BMMC were sensitized with IgE as described in Section 2. Cells were then treated with medium
(control) or CdtBFc (10 g/ml) for 60 min and challenged with DNP-BSA for the
time indicated. Replicate samples were pooled, the cells solubilized, fractionated by
SDS-PAGE and analyzed for Akt and pAkt by Western blot. DNP-BSA induced phosphorylation of Akt within 2–5 min. Akt phosphorylation was reduced in the presence
of CdtBFc . The pAkt intensity is indicated and expressed as inhibition of the relative
control for both 2 and 5 min. Results are representative of three experiments.
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Fig. 7. Assessment of CdtBFc for effects on IgE binding to mast cells. BMMC were incubated in medium alone (panel A), medium containing CdtBFc (panel B; 10 g/ml) or
cells were sensitized with IgE (panels C and D) as described in Section 2. The cells were then exposed to medium only (panels A–C) or CdtBFc (panel D; 10 g/ml) for 2 h.
The level of IgE bound to BMMC was determined by ﬂow cytometry following staining with anti-IgE antibody conjugated to FITC. Mean channel ﬂuorescence (MCF) is shown
and indicates that similar amounts of IgE were present on BMMC in the presence or absence of chimeric toxin. It should also be noted that the anti-IgE antibody does not
recognize CdtBFc (panel B). Results are representative of three experiments.

cence analysis assesses surface IgE as the anti-IgE antibody did not
recognize CdtBFc (panel B; MCF = 5.8).
4. Discussion
The Cdts are a family of heat-labile protein cytotoxins produced
by several different bacterial species including diarrheal diseasecausing enteropathogens such as Escherichia coli, Campylobacter
jejuni, Shigella species, Haemophilus ducreyi and Aggregatibacter
(formerly Actinobacillus) actinomycetemcomitans (Comayras et al.,
1997; Okuda et al., 1997, 1995; Scott and Kaper, 1994; Pickett et
al., 1994; Mayer et al., 1999; Pickett and Whitehouse, 1999). Cdts
are encoded by three genes, designated cdtA, cdtB, and cdtC, which
are arranged as an apparent operon encoding three polypeptides
designated CdtA, CdtB and CdtC with apparent molecular masses
of 28, 32 and 20 kDa, respectively, that form a heterotrimeric holotoxin (Shenker et al., 1999, 2000, 2001; Pickett and Whitehouse,
1999; De Rycke and Oswald, 2001; Thelastam and Frisan, 2004).
There is considerable agreement that the heterotrimeric holotoxin
functions as an AB2 toxin where CdtB is the active (A) unit and the
complex of CdtA and CdtC comprise the binding (B) unit (Nesic et
al., 2004; Elwell et al., 2001; Lara-Tejero and Galan, 2001). In this
regard, we have shown that CdtA and CdtC are required for the
holotoxin to associate with lipid microdomains within lymphocyte
membranes and that the CdtC subunit speciﬁcally binds to cholesterol (Boesze-Battaglia et al., 2006, 2009). Moreover, we recently
determined that the active subunit, CdtB, functions as a lipid phosphatase (Dlakic, 2001). Speciﬁcally, CdtB exhibits PIP3 phosphatase
activity similar to that of the tumor suppressor phosphatases,
PTEN and SHIP1 (Horn et al., 2004; Seminario et al., 2003). Mutation analysis indicates that CdtB-mediated toxicity correlates with
phosphatase activity; furthermore, lymphocytes treated with Cdt
exhibit reduced PIP3 levels. Moreover, lymphoid cell line sensitivity

to CdtB-induced cell cycle arrest correlates with PTEN deﬁciencies,
elevated basal levels of PIP3 and dependence on the PI-3K signaling
pathway for survival and proliferation (Shenker et al., 2007).
In addition to cell proliferation and survival, it is well documented that PIP3 plays a central regulatory role in a diverse array
of cell functions involving a wide range of cell types. Thus PIP3
represents a potent target for modulating cell function, in general,
and mast cell-mediated inﬂammatory disorders in particular. We
propose that the novel lipid phosphatase activity exhibited by CdtB
makes this toxin a potentially useful agent for manipulating cellular
responses for both pharmacologic purposes and for advancing our
understanding of the regulatory role of PIP3. However, CdtB by itself
has minimal capacity to associate with cells and the holotoxin lacks
cell speciﬁcity as it is capable of binding to a wide range of cell types.
In order to harness the pharmacologic potential of CdtB, we chose
to develop a chimeric toxin in which we confer cell binding speciﬁcity by fusing the toxin’s active subunit to the CH2/CH3 region of
IgE thereby targeting the fusion toxin to FcRI-bearing cells. Indeed,
we have demonstrated that the chimeric toxin not only retains
PIP3 phosphatase activity, but exhibits increased enzymatic activity relative to wildtype toxin. The explanation for this elevation in
phosphatase activity is not clear but most likely reﬂects increased
stability of the complex. Additionally, the chimeric toxin selectively
associates with cells expressing FcR1, RBL and BMMC, as opposed
to Jurkat cells which do not express this receptor. Evidence that the
chimeric toxin binding to cells involves FcRI is further supported
by our observation that IgE can block toxin binding.
It is well established that in order for the Cdt holotoxin to
induce toxicity, the active subunit, CdtB, must be internalized following binding. This requirement is consistent with its functioning
as a lipid phosphatase requiring that it gains access to intracellular pools of PIP3. Our observations clearly indicate that RBL cells
treated with CdtBFc exhibit reduced intracellular levels of CdtB
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substrate (PIP3) and increased levels of enzymatic product (PI-3,4P2) providing indirect evidence that the chimera is indeed able
to gain access to intracellular compartments within these cells. It
should be noted that the kinetics of these changes are dependent
upon toxin concentration. The ultimate test, however, was whether
the toxin was capable of preventing mast cell activation. To this
end, we assessed the chimeric toxin for its ability to prevent antigen (DNP-BSA)-IgE-mediated mast cell degranulation. Our results
clearly demonstrate that pre-exposure to CdtBFc results in up to
60% inhibition of antigen-induced degranulation of both RBL and
BMMC. Furthermore, the increase in pAkt, normally observed following antigen-induced activation was inhibited in CdtBFc -treated
BMMC; control cells treated with CdtBWT were unaffected. Moreover these affects were not the result of the chimeric toxin blocking
IgE binding to FcRI since both control and toxin treated mast cells
bound similar amounts of IgE.
The observations reported in this study are the ﬁrst demonstration that direct depletion of PIP3 via increased degradation results
in impaired mast cell function. In this context, it is important to
recognize that our extensive knowledge of the regulatory role for
PIP3 in cellular processes in general, and mast cells, in particular,
has been derived primarily from indirect evidence in which the
synthesis of PIP3 has been altered or degradation blocked. As a key
regulatory molecule, it is essential that PIP3 be maintained at low
levels until its synthesis is stimulated by a variety of signals involving activation of PI-3K which utilizes PI(4,5)P2 to generate PIP3
(Nadler et al., 2001; Bachelet et al., 2006; Furumoto et al., 2006;
Huber et al., 2002, 1998). There are essentially three classes of PI3K (I, II, and III); class I is subdivided into two subclasses, IA and
IB. It is generally accepted that class IA PI-3K isoforms are involved
in FcRI signaling (Kim et al., 2008). Inhibition of PI-3K activity via
mutation or inhibitor results in defective mast cell degranulation
and cytokine production as well as anaphylactic reactions in vivo
(Rivera and Olivera, 2008, 2007; Kim et al., 2008; Marone et al.,
2008). It should be noted that similar results were not noted for all
isoforms suggesting a high level of redundancy of regulatory PI-3K
isoforms in mast cell function. As is often the case with enzyme
inhibitors, the speciﬁcity of PI-3K inhibitors is questionable; for
example, wortmannin and LY294002 target a broad range of PI3K related enzymes (Marone et al., 2008). The importance of PIP3
in mast cell responsiveness has also been demonstrated in studies
that involve reduced expression of the degradative enzymes, PTEN,
SHIP 1 and 2, resulting in sustained increases in intracellular PIP3;
these increases represent a “gain of function” which is manifest
in mast cells as a state of hyperreactivity (Seminario and Wange,
2002; Kyrstal, 2000; March and Ravichandran, 2002).
In summary, the observations reported in this paper provide
further evidence that CdtB represents a highly potent lipid phosphatase. These observations are consistent with our previous
demonstration that the action of the Cdt holotoxin is dependent
upon CdtB-mediated depletion of intracellular levels of PIP3. It
should be noted that our previous studies were based upon the
toxins ability to induce cell cycle arrest and subsequent cell death.
We now demonstrate that this bacterial-derived phosphatase is
also capable of inhibiting a PIP3-dependent functions that do not
involve proliferation. Moreover, these studies further establish the
central regulatory role of this signaling lipid in regulating mast cell
function and provides further evidence that PIP3 is a potent target for pharmacologic intervention to modify mast cell activity and
associated pathologic processes.
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